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Abstract: Sildenafil is an orally administered phosphodiesterase type 5 inhibitor that is 
approved for the treatment of pulmonary arterial hypertension (PAH). The hemodynamic 
effects of sildenafil are mitigated primarily via potentiating the effects of endogenous nitric 
oxide, leading to smooth muscle cell relaxation and reductions in pulmonary arterial pressures 
and pulmonary vascular resistance. When added to standard background therapy in patients 
with idiopathic or associated PAH from congenital heart disease, anorexigen use, or connec-
tive tissue disease, sildenafil treatment results in improved exercise capacity as measured by 
6 minute walk distance, improved hemodynamics, and favorable changes in quality of life. 
Sildenafil use is contraindicated with concomitant nitrate administration, and caution should be 
exercised when used in combination with antihypertensive agents due to risks of precipitating 
hypotension. Side effects are generally mild, and include flushing, headaches, and epistaxis. The 
combination of sildenafil with intravenous epoprostenol is safe and well tolerated, and further 
improves exercise capacity. Sildenafil is approved only for treatment of PAH, and although 
emerging data suggest a potential role in treating other types of pulmonary hypertension, larger 
trials are required to confirm these findings.
Keywords: sildenafil, pulmonary arterial hypertension, phosphodiesterase type 5 inhibitor
Introduction
Pulmonary arterial hypertension (PAH) is a life-threatening disorder characterized by 
progressive remodeling of the pulmonary vasculature, leading to a rise in pulmonary 
arterial pressures and pulmonary vascular resistance that often culminates in right 
ventricular (RV) failure. Despite regional variations in disease epidemiology, a recent 
European registry estimates the prevalence PAH at approximately 15.0 cases/million.1 
Worldwide, prevalence of PAH is likely to rise, given increased awareness among 
physicians, salutatory effects of treatment, increased use of amphetamine stimulants, 
recognition of schistosomiasis as a common etiologic agent in certain regions, and 
greater appreciation for the role of hemoglobinopathies in PAH.2 Prior to the widespread 
use of disease-specific pharmacotherapy, mortality was high, with a median survival 
of 50% at 2.8 years.3 Although few randomized trials have been designed to assess 
survival, observational data suggest improved outcome in the pharmacotherapy era, 
with 2-year survival estimated at 89%.4
Treatment of PAH has evolved dramatically over the past 15 years. Prior to 1996, 
treatment was focused upon symptom control which included management of RV 
failure with diuretics and digoxin, supplemental oxygen therapy to correct hypoxemia, 
and judicious use of calcium channel blockers. The recognition that PAH progression 
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was characterized by vascular remodeling and an imbalance 
between proliferative and anti-inflammatory mediators 
led to the identification of the importance of endothelin, 
prostacyclin, and nitric oxide (NO) in disease initiation and 
progression (Figure 1). These key pathways currently serve 
as targets for disease-specific treatment modalities that have 
revolutionized PAH management, by improving functional 
capacity, hemodynamics, and patient well being.5 In PAH, 
the ideal pharmacologic agents should facilitate vasorelax-
ation and restoration of the balance between apoptosis and 
cellular proliferation, ultimately preserving RV function and 
delaying the onset of right heart failure.6
Sildenafil, an orally administered a phosphodiesterase 
type 5 (PDE-5) inhibitor, targets the NO pathway. The drug 
was first approved for the treatment of erectile dysfunction 
in 1998, and approved for treatment of PAH in 2005.7,8 This 
review will summarize the mechanisms behind the therapeu-
tic efficacy of sildenafil, review the role for sildenafil in the 
treatment of PAH, and highlight emerging roles for sildenafil 
in heart failure and other cardiopulmonary conditions.
Sildenafil background  
and mechanisms of action
The effects of sildenafil in treating both erectile dysfunction 
and PAH are accomplished by enhancing the downstream 
effects of NO mediated vasorelaxation (Figure 2). NO is a 
labile gas produced by NO synthases located in the vascular 
endothelial and airway epithelial cells that freely diffuses 
Figure 1 Cellular mechanisms of sildenafil actions. 
Reproduced with permission from Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004;351:1425–1436.68 Copyright © 
2004 Massachusetts Medical Society. All rights reserved.
Abbreviation: cGMP, cyclic guanosine monophosphate.
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across capillary membranes. On a cellular level, NO stimu-
lates conversion of guanosine triphosphate (GTP) to cyclic 
guanosine monophosphate (cGMP). Intracellular cGMP has 
multiple effects on cellular physiology mediated by activation 
of protein kinases, specifically regulation of ion channels and 
alteration of intracellular cyclic nucleotide concentrations.9 
From a physiological standpoint, NO stimulates dilatation of 
vascular smooth muscle at both the arterial and venous levels. 
Antiproliferative effects of NO have been well described.10,11 
The importance of NO in PAH is magnified because PAH 
is intrinsically associated with reduced endogenous NO 
  production. The ability to maintain NO production in the 
setting of hypoxia may play a role in delaying the onset of 
pulmonary hypertension (PH).12,13
Reduced levels of cGMP have deleterious effects, leading 
to altered calcium handling and subsequent vasoconstriction 
and smooth muscle cell proliferation.6,14 cGMP levels are 
regulated by PDE enzymes. Currently, 11 different families 
of PDE isoenzymes have been identified, which vary in sub-
strate selectivity, tissue location, and mechanism of action 
(Table 1). PDE-5 has been the focus for PAH because the 
PDE-5 enzyme is highly expressed in lung tissue compared 
to other vascular beds, with minimal expression in the sys-
temic circulation.15,16 PDE-5 expression is upregulated in 
PAH, leading to increased metabolism of NO-derived cGMP. 
For these reasons, inhibition of PDE-5 was hypothesized to 
serve as a viable target to enhance NO-mediated physiologic 
effects.17 The utility of PDE-5 inhibition in PAH was first 
demonstrated in 1991, when investigators successfully used 
the PDE-5 inhibitor zaprinast to mitigate alveolar induced 
hypoxia.18 Sildenafil, the first commercially available oral 
PDE-5 inhibitor, was studied in 2001 and demonstrated to 
prevent development of PH in hypoxic mouse models.19
Targeting of the NO pathway with exogenous oral nitrates 
is limited by the rapid development of tachyphylaxis.20 Treat-
ment with PDE-5 inhibitors indirectly modulates the NO 
pathway by acting on a downstream site, thereby obviating 
this problem.
Additional pleotropic mechanisms may contribute to the 
beneficial effects of sildenafil in PAH. Antioxidant properties 
Sildenafil (PDE-5 inhibitor)
cGMP
PDE-5
5´GMP (inactive)
cGMP gated ion channels cGMP gated proteins Protein kinase G
Protein phosphorylation
Calcium modulation
SMC relaxation
Nitric oxide
Guanylyl 
cyclase
Figure 2 Endothelial cell.
Abbreviations: cGMP, cyclic guanosine monophosphate; PDE, phosphodiesterase; SMC, smooth muscle cell.
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have been described in other tissue beds.21,22 Controversy 
exists about the presence of a direct RV inotropic effect of 
sildenafil. The hypertrophied RV demonstrates increased 
tissue expression of PDE-5.23 In healthy individuals, PDE-5 
is expressed in the coronary arteries, but is not typically 
found in cardiac myocytes. One study comparing sildenafil 
to inhaled NO (iNO) demonstrated comparable reductions in 
PA pressures and pulmonary vascular resistance (PVR), but 
increased cardiac index (CI) was seen only with sildenafil 
treatment, consistent with an inotropic effect.24 However, 
other investigators, examining load-independent measures 
of myocardial performance, found no changes in systolic 
or diastolic function with sildenafil treatment.25 Circulating 
endothelial progenitor cells are reduced in idiopathic PAH 
and congenital PAH, and treatment with sildenafil has been 
shown to increase these cells to levels consistently higher 
than other PAH therapies.26 Sildenafil also inhibits PDE-1, 
which is expressed in low levels in the pulmonary circula-
tion under baseline conditions but is upregulated in the 
disease state.27 The clinical significance of these findings 
remains uncertain. Ultimately, modulation of cGMP leads 
to improved calcium handling and restoration of the balance 
between apoptosis and smooth cell proliferation, resulting in 
vascular reverse remodeling.
Drug pharmacokinetics  
and interactions
Maximum plasma concentrations of sildenafil dosed at the 
Food and Drug Administration (FDA) approved schedule of 
20 mg 3 times daily are achieved 1 hour after administration, 
with a half-life of approximately 4 hours. Bioavailability is 
approximately 40%, which is reduced to 29% following a 
large meal.28 In the elderly (age .65 years) the clearance 
of sildenafil is impaired, with increased drug half-life and 
maximum serum concentrations.29 The   pharmacokinetics 
of sildenafil are not altered in the setting of mild to mod-
erate renal insufficiency. Although serum levels can rise 
in severe impairment, dosing changes are usually not 
required.29 Similarly, in patients with Child’s A or B   cirrhosis, 
despite increased drug levels, dose adjustments are rarely 
necessary.29
Sildenafil is metabolized primarily by the hepatic 
cyto  chrome P450 (CYP) 3A4 enzymes and to a lesser 
extent by CYP2C9 enzymes. The primary metabolite, 
  N-desmethylsildenafil, maintains PDE-5 specificity, but 
with reduced potency, and plasma levels approaching 40% 
of primary compound.28 Careful monitoring is advisable with 
coadministration with CYP3A4 inducers (carbamazepine, 
phenytoin, nevirapine), as sildenafil dose increases may be 
necessary. Bosentan is an inducer of the CYP3A4 pathway, 
and the use of these drugs in combination will be discussed 
later in this review. Sildenafil is currently listed by the FDA 
as a category B drug in pregnancy.30 There are only small 
case series examining drug safety in pregnancy, and caution 
is advised in this regard.31
Drug side effects
Review of the pivotal SUPER 1 study demonstrate that 
the most frequent placebo subtracted side effects were 
epistaxis (8%), headache (7%), and flushing (6%).8 There 
was a dose-dependent increase in the incidence of drug-
related side effects, including flushing, headache, and blurry 
vision. No significant laboratory abnormalities were identi-
fied. Retinal hemorrhage occurred more commonly in the 
sildenafil-treated group (1.4% vs 0%), but most patients who 
developed this condition were taking oral anticoagulants. 
Because of a shared and common pathway of increased 
NO-mediated effects, concomitant administration with oral 
Table 1 Phosphodiesterase isoenzymes
PDE type Function Primary distribution
1 Ca2+ modulation; smooth cell proliferation Smooth muscle cells; proliferating tissue
2 Ca2+ channel regulation; aldosterone secretion Brain, adrenal glands
3 Cardiac contractility Cardiac myocytes, vascular smooth muscle
4 Immunological and inflammatory signaling Neural and endocrine tissue
5 Penile erection; regulation of airway smooth muscle cells Penile tissue, airway smooth muscle cells
6 Eyesight Photoreceptor cells in retina
7 Regulation of T lymphocytes T lymphocytes and skeletal muscle tissue
8 T cell activation Testis and thyroid gland
9 Unclear Spleen, intestine, heart, brain
10 Unclear widely expressed in all tissue beds
11 Sperm capacitation Vascular smooth muscle, penis, cardiac myocytes
Adapted from Barst.69
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nitrate   medications can potentiate the effects of either agent, 
and their use together is contraindicated.32 Administration of 
sildenafil to patients taking nitrate medications can produce 
dramatic reductions in blood pressure (systolic blood pressure 
drop in excess of 50 mmHg) and syncope.33 Sildenafil should 
not be administered to patients who have taken any oral or 
sublingual preparation within the previous 24 hours. While 
larger doses of sildenafil have been associated with significant 
reduction in systolic blood pressure approaching 10 mmHg, 
the FDA-approved dose of 20 mg by mouth 3 times daily 
has not been shown to significantly affect blood pressure.34 
Blurry vision has been described at higher doses, primarily 
due to minor inhibition of PDE-6 located in the eyes.
Nonarteritic anterior ischemic optic neuropathy (NAION) 
is a common cause of acute optic neuropathy in the elderly. 
Anecdotal reports and cases series suggested increased risks 
of NAION in sildenafil-treated patients. However, pooled 
data from clinical trials of all three commercially available 
PDE-5 inhibitors (sildenafil, tadalafil, vardenafil) suggested 
no increased risk of NAION.35 Patients at highest risk for 
development of NAION are those who have previously suf-
fered NAION in one eye, and those with other risk factors for 
vascular disease, including diabetes mellitus. Although these 
findings are reassuring to health care providers, it remains 
advisable to monitor for visual changes, and to seek prompt 
medical attention for sudden vision loss. Uncommon drug 
effects, including a case report of thrombocytopenia, have 
been described.36
Clinical trial experience
The first case report demonstrating a clinical benefit of 
sildenafil in PAH was published in 2000.37 Earlier work had 
suggested utility of sildenafil in other cardiopulmonary con-
ditions, including weaning mechanically ventilated patients 
with iNO-dependent respiratory failure.38 Building on this 
promising early experience, single-center studies were com-
pleted that suggested significant clinical efficacy and both 
functional and hemodynamic improvement in PAH.39 Taken 
together these studies suggested that sildenafil, in a dose-
dependent manner, had durable and sustained pulmonary 
vasodilator effects.
The SUPER-1 trial (Sildenafil Use in PUlmonary hypER-
tension) commenced enrollment in 2002, and randomized 
patients with PAH to treatment with either sildenafil (20 mg, 
40 mg, 80 mg) 3 times daily or placebo.8 The primary end-
point in this study, similar to most PAH trials, was assess-
ing exercise capacity as measured by changes in 6 minute 
walk distance (6MWD) at 12 weeks. Secondary endpoints 
included changes in invasive hemodynamic parameters, 
BORG dyspnea score, clinical worsening, and health related 
quality of life (QoL). The study was restricted to patients with 
idiopathic PAH, and acquired PAH from connective tissue 
disease (CTD), congenital heart disease (CHD), or previous 
anorixegen use, and composed of patients with moderate 
disease severity (Table 2), who were predominantly World 
Health Organization (WHO) functional class II (39%) and 
III (58%), and had a mean 6MWD of 344 m. The mean age 
of patients included in the study was 49 years, and approxi-
mately three-fourths of patients were female.
After 12 weeks, the mean placebo corrected increase 
in 6MWD was 45 m. A trend towards improved exercise 
capacity was detected as early as 4 weeks. Sildenafil treat-
ment was associated with a statistically significant number of 
patients who improved by at least one functional class (21%, 
P = 0.003). There were no significant differences between 
the sildenafil- and placebo-treated groups in BORG dyspnea 
score, or the incidence of clinical worsening, defined as a 
combined endpoint of death, lung transplantation, hospital-
ization for PAH or need to institute combination therapy.
Patients who completed the study were eligible to enroll 
in an extension study, where doses were uptitrated to 80 mg 
by mouth 3 times daily. The results of the extension study 
have not yet been published. Subgroup analysis from the 
SUPER-1 study in 84 patients with CTD demonstrated that 
the drug was equally safe and efficacious this patient popula-
tion.40 Analysis of QoL measures demonstrated that treatment 
with sildenafil significantly improved physical functioning, 
and general health, vitality, and well-being.
Based primarily upon the results of SUPER-1 study, in 
2005, sildenafil was approved for the treatment of PAH in 
both the United States and Europe at the 20 mg 3 times daily 
dose. Although there were no differences in 6MWD between 
the three doses during the pivotal trial period, dose-dependent 
changes in hemodynamic parameters, particularly mean pul-
monary arterial pressure (mPAP) and PVR, were identified. 
Table 2 WHO functional classification of pulmonary hypertension
Classification Symptoms
Class i No limitations in daily physical activities. No 
symptoms of dyspnea with routine exertion
Class ii Mild symptoms with exertion, including dyspnea and 
fatigue. No symptoms at rest
Class iii Moderate dyspnea with routine activities and 
activities of daily living. No symptoms at rest
Class iV inability to perform even minimal activities. Signs 
and symptoms of right heart failure may be present. 
Dyspnea present at rest
Adapted from McLaughlin and McGoon.70
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Additional small studies have suggested safety and efficacy 
of higher doses of sildenafil, but obtaining insurance approval 
for these higher doses remains challenging.41
Clinical use of sildenafil
Sildenafil is indicated in patients with mild to moderate 
pulmonary hypertension (WHO FC II-III).42 There are no 
data to support treatment in asymptomatic individuals, and 
the drug should not be used as a first-line agent in markedly 
symptomatic patients (WHO FC IV , 6MWD ,100 m). When 
considering initiating treatment with sildenafil, the physician 
must carefully examine the existing medication list, monitor 
for drugs that may potentiate an interaction (alpha-blockers, 
nitrates) and assess for systemic hypotension that may worsen 
with treatment.
Currently, sildenafil is one of nine FDA-approved phar-
macologic therapies for PAH. These include treatments 
involving continuous infusions, using hand-held inhaled 
devices, and pills. Before choosing an agent, several fac-
tors should be assessed, including disease severity, existing 
comorbidities, patient compliance, family support, and drug 
side effects–interactions. Regardless of chosen pharma-
cotherapy, regular follow up, and surveillance for disease 
progression and development of RV failure are critical in 
disease management.
There are very few head to head trials comparing differ-
ent agents. One small study comparing high dose sildenafil 
(dose titration to 50 mg 3 times daily) to bosentan dosed at 
125 mg by mouth twice daily, demonstrated no significant 
change in the primary endpoint (RV mass), or secondary 
endpoints, including 6MWD and B-type natriuretic peptide 
levels.43 In patient with WHO FC II-III disease, most experts 
recommend initial therapy with an oral agent with careful 
follow up for disease progression.42 These recommendations 
stem primarily from the efficacy of the oral agents, coupled 
with desire to avoid potential infectious complications with 
continuous infusion therapy and the cumbersome nature of 
inhaled therapy, which requires 4 to 9 treatments daily. An 
advantage of PDE-5 inhibitor over the endothelin receptor 
antagonists ambrisentan and bosentan, is that therapy with 
PDE-5 inhibitors does not require safety monitoring with 
monthly liver function tests.
Sildenafil in other acquired PAH
Smaller studies have been completed in patients who were not 
eligible for the larger scale phase III clinical trials. Patients 
with end-stage liver disease are susceptible to development 
of portopulmonary hypertension, which, if untreated, is a 
contraindication for liver transplantation. While epoprostenol 
has long been the gold standard for treatment of portopul-
monary hypertension, smaller studies suggest that in milder 
cases, sildenafil treatment can be safely used as a bridge to 
liver transplantation.44
Combination therapy
The rational for combination therapy stems from using 
different classes of medications target the disease from 
multiple mechanisms. As a general rule, efficacy should 
be maximized, while minimizing drug toxicity. Despite the 
number of agents available, limited published data are avail-
able to guide decision making in this regard. Given the costs 
associated with PAH therapy and potential for drug interac-
tions and side effects, caution is advised when attempting 
combination therapy. The largest clinical trial evaluating 
combination therapy studied adding sildenafil, at doses 
ranging from 40 mg 3 times daily to 80 mg 3 times daily, to 
patients on stable doses of intravenous epoprostenol.45 The 
study included 267 patients with predominantly idiopathic 
PAH (79%), and those with WHO FC II (26%) and WHO 
FC III (66%) symptoms. Addition of sildenafil was associ-
ated with a significant placebo-adjusted increase in 6MWD 
of 26 m (P = 0.0009) and increased time to clinical worsen-
ing. Hemodynamic improvements were noted with addition 
of sildenafil, including a reduction in mPAP of 3.9 mm mg 
(P = 0.00003). Health-related QoL was improved with 
sildenafil treatment, despite no significant changes in the 
Borg dyspnea score.
A few small single center studies have reported safety 
in adding sildenafil in combination with inhaled iloprost. 
The study with the longest follow up evaluated patients who 
experienced clinical worsening after treatment with iloprost. 
Fourteen patients were randomized to treatment with sildena-
fil or placebo, and the sildenafil-treated group experienced 
significant and durable improvements in 6MWD.46 The tim-
ing for introduction of a second agent remains unresolved. 
Based upon available literature, most therapies require 12 to 
16 weeks for a maximal response. Additional improvements 
in exercise capacity as measured by 6MWD have not been 
demonstrated in nonblinded extension studies of the pivotal 
drug trials. Whether to initiate combination therapy prior to 
clinical deterioration in monotherapy, or earlier on in the 
course of disease, has not been established.
Coadministration of bosentan (a hepatic enzyme inducer) 
and sildenafil reduces plasma levels of sildenafil and increases 
bosentan concentrations, though the clinical significance of 
this remains uncertain.47 As described earlier, bosentan 
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induces expression of CYP2C9 and CYP3A4, which are 
involved with metabolism of sildenafil, and can decrease 
the pharmaceutical area under the curve by approximately 
55%.47 To determine if any clinically relevant interaction 
existed, the COMPASS I study investigated the acute hemo-
dynamic effects of sildenafil addition to patients on long-term 
bosentan therapy.48 Sildenafil administration reduced PVR 
by 15%, comparable to that seen with sildenafil montherapy 
in treatment-naïve patients. Despite the pharmacokinetic 
interaction between the agents, most experts believe that 
alterations in treatment effects of either drug are not appar-
ent with the combination, and dose adjustment are usually 
not required. There are no clinically relevant interactions 
between ambrisentan and sildenafil.49
Broad treatment guidelines apply to all patients with 
PAH. Hypoxemia is a potent pulmonary vasoconstrictor, 
and it is advisable for oxygen to be administered to maintain 
saturations above 90%. Right heart failure and symptoms of 
congestion are common, and therapy with diuretics is often 
required to maintain an optimal volume state. Calcium chan-
nel blocker use should be restricted to patients with WHO FC 
I-III patients with idiopathic PAH who demonstrate a positive 
response to a vasodilator challenge at the time of right heart 
catheterization. A positive response is defined as a decline 
in the mean pulmonary artery pressure of .10 mmHg 
and to a level less than 40 mmHg, with an unchanged or 
improved cardiac index. Oral digoxin has not been studied 
in a controlled fashion, but in patients with advanced disease 
exhibiting signs and symptoms of RV failure, or those with 
atrial tachyarrhythmias who may not tolerate beta blockers, 
therapy with digoxin may be beneficial. In patients with 
IPAH, anticoagulation with coumadin is recommended in 
absence of contraindications.
Costs of PAH therapy
Society is becoming increasingly aware of the costs of 
health care. Of the nine FDA-approved therapies, only 
epoprostenol is available in the generic from. Compared 
to drugs routinely used to treat common cardiopulmonary 
conditions (hypertension, dyslipidemia, obstructive lung 
disease) PAH pharmacotherapy is considerably more costly. 
Uninsured or underinsured patients will be unable to afford 
the costs of PAH pharmacotherapy in the absence of other 
financial support. It is therefore incumbent upon the physi-
cian to perform a thorough diagnostic evaluation to confirm 
the diagnosis of PAH, and exclude more common condi-
tions, including obstructive lung disease, obstructive sleep 
apnea, and pulmonary venous hypertension from systolic 
or diastolic dysfunction. A recent study examined the costs 
of PAH pharmacotherapy. The investigators obtained cost 
information from US medicare and medicaid data, and uti-
lizing a Markov-type model, determined that in medically 
comparable patients, treatment with sildenafil was less costly 
and associated with a net increase in quality adjusted life-
years.50 In insured patients who have adequate prescription 
drug coverage, we feel that the factors described previ-
ously, and not the cost of therapy, should drive decisions on 
pharmacotherapy.
Other PDE-5 inhibitors
Tadalafil is an orally administered PDE-5 inhibitor cur-
rently approved for treatment erectile dysfunction and PAH. 
A 16-week randomized, placebo-controlled study comparing 
tadalafil at doses ranging from 2.5 mg to 40 mg to placebo 
in patients with PAH was recently published.51 Similar to 
the SUPER-1 Study, the primary endpoint in this trial was 
change in functional capacity as estimated by 6MWD. The 
mean placebo-corrected improvement in 6MWD was 33 m. 
When patients on background therapy with bosentan were 
removed, and only PAH treatment-naïve patients analyzed, 
the treatment effect was 44 m, comparable to that noted 
with sildenafil in the SUPER-1 study. Additionally, the 
drug improved QoL, and was associated with comparable 
improvements in hemodynamic patterns. Tadalafil levels 
are reduced with coadministration with bosentan,52 and the 
FDA-approved dose of tadalafil is 40 mg daily. Vardenafil 
is a commercially available PDE-5 inhibitor used for the 
treatment of erectile dysfunction that is not FDA approved 
for the treatment of PAH.
Non-WHO group-1 pulmonary 
hypertension
Multiple conditions result in development of pulmonary 
hypertension, but are not characterized as PAH (Table 3). 
Phase III clinical trials have excluded these patients, and 
therefore, sildenafil is not FDA approved for treatment 
in these conditions. Smaller studies have suggested poten-
tial utility in several populations. In patients with chronic 
thromboembolic pulmonary hypertension (CTEPH), where 
anatomy is not favorable for surgical pulmonary arterial 
thromboendarterectomy, a potential beneficial effect to long-
term sildenafil treatment has been suggested.53 Sildenafil may 
have a useful role in management of post-heart transplant 
RV dysfunction and to expedite weaning from inotropes.54 
A small single-center study investigated high-dose sildenafil 
treatment in patients with pulmonary sarcoidosis (WHO 
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Group V PH) where sildenafil treatment was associated 
with reductions in PA pressures, PVR, and improved cardiac 
index, but no change in 6MWD.55 In chronic obstructive 
pulmonary disease, single-dose treatment with sildenafil has 
been shown to reduce PA pressure, irrespective of baseline, 
but have no impact on cardiac output, stroke volume, or 
exercise capacity.56 In patients at high altitudes who are 
continuously exposed to hypoxic conditions, sildenafil has 
demonstrated beneficial effects in reducing PA pressures.57 
In one study of patients with pulmonary fibrosis, sildenafil 
usage at 50 mg daily reduced pulmonary vascular resistance, 
improved V/Q mismatch, and increased partial pressure 
of oxygen.58 In patients with systemic sclerosis, sildenafil 
treatment in patient with refractory Raynaud’s with digital 
ulcers was associated with reduced frequency and duration 
of Raynaud’s attacks, and improved capillary flow.59 Despite 
these promising initial data, larger clinical trials, with better 
delineation of the target populations and study endpoints, are 
warranted. Given the costs, unproven benefits, and potential 
side effects of therapy, it is generally not advisable to use 
sildenafil for conditions other than WHO Group I PH.
Sildenafil in heart failure
The most common cause of right heart failure is longstand-
ing left heart failure and development of pulmonary venous 
hypertension. Over time, if left untreated, some patients 
can develop structural changes in the pulmonary arteries 
with resultant increase in pulmonary vascular resistance.60 
Sildenafil has been shown to be well tolerated among severe 
end-stage heart failure patients undergoing transplant evalu-
ation and as an acute screening agent for fixed pulmonary 
hypertension that would otherwise be a contraindication 
to heart transplantation.61 Impaired NO generation and 
  utilization contributes to the abnormal cardiovascular phe-
notype in congestive heart failure. Based upon these obser-
vations, sildenafil is receiving increasing attention from the 
heart failure community.
From a historical perspective, PDE inhibitors were used 
with great caution in heart failure, because the PDE-3 inhibi-
tor milrinone, which increases myocellular cyclic adenosine 
monophosphate (cAMP) levels, is associated with increased 
mortality in heart failure.62 However, sildenafil, through its 
high specificity for PDE-5, is believed to be far safer in this 
regard. From a safety standpoint, sildenafil has been studied 
in doses ranging from 25 to 100 mg in patients with erectile 
dysfunction and heart failure and appears to be safe and 
well tolerated.61
Melonovsky et al studied the acute hemodynamic 
effects of sildenafil administration in heart failure.63 Fol-
lowing dosing with 40 mg sildenafil, reductions in PVR 
and improvements in PA compliance were noted. Increased 
intracellular levels of cGMP were reported, suggesting that 
PDE5 inhibition restores sensitivity of pulmonary vascular to 
endogenous cGMP-dependent vasodilators. Additional stud-
ies of patients with heart failure and pulmonary hypertension 
demonstrated that sildenafil treatment was associated with 
improved ventilator efficiency, as determined by Ve/VCO2 
slope by cardiopulmonary stress testing, and correlated with 
drops in pulmonary vascular resistance and improvement in 
RV ejection fraction.64 Sildenafil may improve RV systolic 
function in patients with heart failure complicated by PH.64 
A small, placebo-controlled randomized study in congestive 
heart failure patients demonstrated that 4 weeks of sildenafil 
administration improved functional capacity, ventilator 
efficiency, and pulmonary hypertension.65 In stable heart 
failure patients, sildenafil treatment improves mVO2 max and 
improves endothelial function as measured by brachial artery 
flow-mediated dilation, suggesting endothelium-mediated 
attenuation of exercising muscle oversignaling.66 Nitrates 
are commonly used in heart failure, and are contraindicated 
with sildenafil administration. However, a small study 
demonstrated safety and efficacy of combing nitrates with 
sildenafil to further reduce PA pressures in advanced heart 
failure.67 Taken together, the experience of sildenafil in heart 
failure appears promising and provocative, and a potential 
novel application.
Conclusions
Sildenafil has emerged as a safe and efficacious pharmaco-
therapy for PAH. Longer-term studies, examining the effects 
Table 3 WHO classification of pulmonary hypertension
WHO classification Disease states
Group I: PAH idiopathic PAH, familial PAH, 
associated PAH
Group II: Pulmonary hypertension 
with left heart disease
Valvular heart disease, systolic 
or diastolic dysfunction
Group III: Pulmonary hypertension 
associated with lung disease or 
hypoxemia
OSA, iLD, COPD, chronic 
hypoxemia
Group IV: CTEPH Thromboembolic occlusion 
of the distal or proximal 
pulmonary vasculature
Group V: Miscellaneous Sarcoidosis, fibrosing 
mediastinitis
Adapted from McLaughlin et al.42
Abbreviations:  PAH,  pulmonary  arterial  hypertension;  OSA,  obstructive  sleep 
apnea; iLD, interstitial lung disease; COPD, chronic obstructive pulmonary disease; 
CTEPH, chronic thromboembolic pulmonary hypertension.
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of therapy on disease remodeling overall survival have yet to 
be completed. Combination therapy is an exciting develop-
ment in the treatment of PAH. A favorable side effect profile 
and acceptable dosing regimen make sildenafil an attractive 
option for combination therapy, and studies are underway 
examining multiple drug combinations. By enhancing 
downstream effects of NO, there is potential for sildenafil 
to have utility in treating various conditions with endothelial 
dysfunction and regional alterations in blood flow.
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